Diligence memo · auto-generated · as of July 2, 2026
Affinia Therapeutics Inc.
Affinia Therapeutics Inc. has raised $170M over 4 rounds; too few niche peers to rank its valuation yet.
Businessfiled
Affinia Therapeutics Inc. operates in Pharma, based in WALTHAM.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Affinia Therapeutics Inc. has raised $170M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $110M on 2021-04-20.
Most recent recorded round closed around 2025-09-16.
Valuation (modeled)modeled
Provath models Affinia Therapeutics Inc. at approximately $100M (range $63M–$121M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Too few comparable companies in this niche to rank the valuation fairly yet.
Financing rhythm & timingmixed
Historic cadence: a new round about every 24 months.
Last raise 9 mo ago; this sector typically re-raises about every 16 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 8.3× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 95% of Pharma peers (310 compared).
Modeled value ranks above 66% of those peers.
Closest niche peers: Cognito Therapeutics Group, Inc., Star Therapeutics LLC.
Peoplefiled
20 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.